Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo
read more » Discuss Add this link to...Bury Add to:
| Bookmarks